ESR1 and prostate carcinoma: Low GEN concentrations applied for 1–2 weeks were sufficient to reduce DNA methylation at the promoter of GSTP1, a Phase-II metabolizing enzyme commonly silenced in prostate cancer, with subsequent weak mRNA re-expression in ER-negative MDA-MB-468 but not in ER-positive MCF-7 cells.